Leal, Ticiana A.
University of North Carolina at Chapel Hill · Memorial Sloan Kettering Cancer Center · Emory University · University of California, Irvine · Virginia Cancer Specialists · Tennessee Oncology · Winship Cancer Institute · UNC Lineberger Comprehensive Cancer Center
6 papers on CoChatORCID 0000-0002-3735-9063
Most cited papers
- Verified
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021: Featured Updates to the NCCN Guidelines
Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., D’Amico, T. A., et al. (2021) · Journal of the National Comprehensive Cancer Network
Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment
Cited by 948
- Verified
Updated Overall Survival and PD‐L1 Subgroup Analysis of Patients With Extensive‐Stage Small‐Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)
Liu, S. V., Reck, M., Mansfield, A. S., Mok, T., Scherpereel, A., Reinmuth, N., Garassino, M. C., De Castro Carpeno, J., Califano, R., Nishio, M., et al. (2021) · Journal of Clinical Oncology
Lung Cancer Research StudiesCancer Immunotherapy and Biomarkers
Cited by 862
- Verified
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C
Yaeger, R., Weiss, J., Pelster, M. S., Spira, A. I., Barve, M., Ou, S.-H. I., Leal, T. A., Bekaii-Saab, T. S., Paweletz, C. P., Heavey, G. A., et al. (2023) · New England Journal of Medicine
Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments
Cited by 527
- Verified
First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRAS G12C Solid Tumors (KRYSTAL-1)
Ou, S.-H. I., Jänne, P. A., Leal, T. A., Rybkin, I. I., Sabari, J. K., Barve, M. A., Bazhenova, L., Johnson, M. L., Velastegui, K. L., Cilliers, C., et al. (2022) · Journal of Clinical Oncology
Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling
Cited by 322
- Verified
KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation
Jänne, P. A., Rybkin, I. I., Spira, A. I., Riely, G. J., Papadopoulos, K. P., Sabari, J. K., Johnson, M. L., Heist, R. S., Bazhenova, L., Barve, M., et al. (2020) · European Journal of Cancer
Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling
Cited by 140
- Verified
KRYSTAL-1: activity and safety of adagrasib (MRTX849) in patients with colorectal cancer (CRC) and other solid tumors harboring a KRAS G12C mutation
Johnson, M. L., Ou, S. H. I., Barve, M., Rybkin, I. I., Papadopoulos, K. P., Leal, T. A., Velastegui, K., Christensen, J. G., Kheoh, T., Chao, R. C., et al. (2020) · European Journal of Cancer
Colorectal Cancer Treatments and StudiesProtein Kinase Regulation and GTPase Signaling
Cited by 77
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free